Status and phase
Conditions
Treatments
About
A phase 3, multi-center, single-group, open-label study to evaluate the efficacy and safety of DKF-MA102 in patients with prostate cancer.
Full description
This study is conducted to confirm the pharmacodynamic effects, efficacy, and safety of DKF-MA102 in prostate cancer patients by measuring the changes in serum testosterone levels.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
154 participants in 1 patient group
Loading...
Central trial contact
Dami Jeon, Bachelor; Seo hyun Kim, Bachelor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal